Chronic Kidney Disease Treatment Market Sets New Record, Predicted to Hit USD 47.9 Billion by 2032, at 4% CAGR: Claims AMR

The chronic kidney disease treatment market size was valued at $32 billion in 2022, and is estimated to reach $47.9 billion by 2032, growing at a CAGR of 4% from 2023 to 2032.

• CAGR: 4%
• Current Market Size: USD 32 Billion
• Fastest Growing Region: APAC
• Largest Market: North America
• Projection Time: 2022-2032
• Base Year: 2022

  𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭-https://www.alliedmarketresearch.com/request-sample/107605

What are drivers of Chronic Kidney Disease Treatment Market ?

The chronic kidney disease treatment industry is experiencing significant growth driven by increased research and development endeavors for introducing innovative drugs and enhancing existing pharmaceuticals. Additionally, a growing number of approvals from government regulatory bodies are presenting lucrative prospects for the market in treating chronic kidney disease.

Moreover, investments in research and development are driving progress in drug discovery, formulation, and treatment alternatives for patients with chronic kidney disease (CKD). Various entities such as pharmaceutical companies, academic institutions, and research organizations are actively committing resources to R&D, aiming to identify novel therapeutic targets, create more potent drugs, and improve existing treatment approaches. The heightened emphasis on research and development is a response to the increasing global prevalence of CKD, underscoring the demand for more effective and advanced treatment options.

Recent Product Approval in Chronic kidney disease treatment market 

• In May 2023, AstraZeneca’s Farxiga (dapagliflozin) received approval in the U.S. to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER Phase III trial.
• In February 2023, AstraZeneca’s Forxiga (dapagliflozin) received approval in the European Union to extend the indication for heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left ventricular ejection fraction (LVEF), including HF with mildly reduced and preserved ejection fraction (HFmrEF, HFpEF).

Recent Acquisition in Chronic kidney disease treatment market  

In March 2022, B. Braun SE, one of the world’s leading medical technology companies acquired Intermedt Medizin & Technik GmbH, a specialist in the preparation of dialysis concentrates. With this acquisition the Intermedt product portfolio will be permanently integrated into B. Braun comprehensive range of products and services for dialysis therapy.

Key findings of the study  

• On the basis of treatment, the drugs segment dominated the chronic kidney disease treatment market size in 2022.
• On the basis of end user, the hospital segment dominated the chronic kidney disease treatment market size  in 2022.
• On the basis of region, North America dominated the market in 2022. However, Asia-Pacific is expected to be the fastest growing region during the forecast period.

𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (238 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬) @ https://www.alliedmarketresearch.com/chronic-kidney-disease-treatment-market/purchase-options

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic kidney disease treatment market analysis from 2022 to 2032 to identify the prevailing chronic kidney disease treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the chronic kidney disease treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global chronic kidney disease treatment market trends, key players, market segments, application areas, and market growth strategies.

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐘𝐨𝐮𝐫 𝐄𝐯𝐞𝐫𝐲 𝐃𝐨𝐮𝐛𝐭 𝐇𝐞𝐫𝐞:

https://www.alliedmarketresearch.com/purchase-enquiry/107605

𝐓𝐨𝐩 Chronic Kidney Disease Treatment 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬

• AbbVie Inc.
• Baxter International Inc.
• Fresenius SE and Co. KGaA
• AstraZeneca plc
• Teva Pharmaceutical Industries Ltd.
• B. Braun SE
• F. Hoffmann-La Roche Ltd.
• Becton, Dickinson and Company
• Johnson & Johnson
• Pfizer Inc.

𝑶𝒕𝒉𝒆𝒓 𝑻𝒓𝒆𝒏𝒅𝒊𝒏𝒈 𝑹𝒆𝒑𝒐𝒓𝒕𝒔 𝒊𝒏 𝑳𝒊𝒇𝒆 𝑺𝒄𝒊𝒆𝒏𝒄𝒆 𝑫𝒐𝒎𝒂𝒊𝒏-

Flow Diverters Market https://www.alliedmarketresearch.com/flow-diverters-market-A17519

Hyperhidrosis Treatment Market https://www.alliedmarketresearch.com/hyperhidrosis-treatment-market-A17523

Nose Reconstruction Market https://www.alliedmarketresearch.com/nose-reconstruction-market-A13217